Country for PR: United Kingdom
Contributor: PR Newswire Europe
Thursday, October 06 2022 - 17:30
Servier unveils its 2030 ambition and reveals a new visual identity
PARIS, Oct. 6, 2022 /PRNewswire-AsiaNet/ --

A new ambition by 2030 to accelerate its transformation dynamic
A visual identity, a marker of the successful transformation of the Group, its 
ambitions and its renewal 

Servier today unveils its 2030 ambition as well as a new visual identity that 
reflects the transformation undertaken by the Group, bringing visible results. 
The Group intends to accelerate its transformation dynamics in order to ensure, 
over the long term, its independence and its creation of value for all its 
stakeholders. Servier confirms its commitment to making a meaningful social 
impact and contributing to a sustainable world. 

A transformation that leads to results

Servier committed in 2015 to a transformation aimed at sustainably improving 
the company's performance and ensuring the sustainability of its unique 
governance model for the ultimate benefit of patients. Being governed by a 
foundation also gives the Group a long-term vision, perfectly adapted to the 
long cycles of the pharmaceutical sector. 

In recent years, Servier has strengthened its leadership in cardiovascular 
diseases, the leading cause of mortality worldwide[1] – Servier is the 3rd 
largest global pharmaceutical group in cardiology and in hypertension.[2] 
Drawing on recognized scientific know-how, the Group has developed a wide range 
of treatments distributed in 150 countries. Servier has significantly invested 
in incremental innovation, including Single Pill Combinations (SPCs), several 
medicines combined into a single tablet, which leads to better patient 
compliance and contributes to savings for the healthcare system. Servier is 
also a renowned global leader in venous diseases, thanks to daflon(R) which is 
an important part of the Group's growth.

Servier has made a major shift in oncology as a new pillar of strategic growth. 
The Group allocates over 50% of its R&D budget to it, with the ambition to 
become a renowned and innovative player in the development of therapeutic 
solutions targeting hard-to-treat cancers. Servier leads its R&D programs 
around two approaches: immuno-oncology and targeted therapies. Over the past 
four years, the Group has significantly strengthened its position in oncology 
thanks to more than Euro6 billion investments, including two major acquisitions 
which have made it possible to establish a presence in new strategic 
territories such as the United States and Japan. The Group's major investment 
in oncology today results in a rich pipeline of 39 R&D projects and seven 
medicines available to patients.  

The Group also consolidated its generic business through national champions 
with strong brands such as Biogaran in France, Egis in Eastern Europe, Pharlab 
in Brazil and Swipha in Nigeria. This activity opens access to quality care for 
the largest number of people and contributes to lowering healthcare costs.

The transformation has impacted all the Group's activities, including R&D, 
which has undertaken a transformation plan based on three pillars that support 
progress and therapeutic performance: a patient-centric approach, a more 
efficient organization with a collaborative dynamic, and a refocusing on four 
therapeutic areas (oncology, cardiometabolism, neuroscience and 
immuno-inflammation). In its ambition to build a very open, dynamic and 
productive research for the benefit of patients, the opening of the Servier 
Research and Development Institute at Paris-Saclay in 2023 is a major step in 
the transformation of R&D. The result of an investment of more than Euro370 
million, it is situated at the center of a global scientific and technological 
innovation cluster. The future Institute will be the heart of the Group's 
global R&D organization and will work cross-functionally with Servier's other 
R&D centers based in Denmark (Ballerup), the United States (Boston) and Hungary 
(Budapest). It will accommodate 1,500 employees and will include an incubator 
housing approximately 15 start-ups.

The Group has also accelerated its digital transformation to create value for 
patients and healthcare stakeholders, while unlocking the potential of teams, 
through new agile and efficient ways of working as well as a transformed 

Relying on a solid foundation, the Group is now able to confirm its trajectory 
to 2025 – a revenue of
Euro6 billion, including Euro1 billion in oncology, and a Group EBITDA of 
Euro1.3 billion – and to ambitiously address the second strategic step of its 
transformation plan by 2030.  

Olivier Laureau, President of Servier, says: "I want to thank all the employees 
of the Group who contribute to the success of the company's profound 
transformation, recognized worldwide by healthcare professionals, patient 
associations and our partners. The path we have travelled has allowed us to 
value our uniqueness: Servier is a group governed by a foundation whose 
ultimate beneficiary is and will always be the patient. This independence 
allows us to invest in the long-term for the development of innovative 
therapeutic solutions to meet high unmet medical needs."

A 2030 vision and ambition to accelerate the Group's transformation 

Building on the 2025 goals as an important milestone, Servier has set a 2030 
ambition to accelerate its transformation. The Group thus intends to achieve a 
turnover of Euro8 billion in 2030 with an EBITDA of more than 30% through a 
strategy based on three pillars:

1 – Be a mid-size, focused and innovative player in oncology as well as in 
neuroscience and immuno-inflammation

Thanks to the major investments made in R&D, the Group has strong innovation 
capabilities and a rich pipeline of projects targeting pathologies with a high 
unmet medical need. Servier thus intends to launch a new molecular entity, or a 
new indication, every year in oncology and to achieve a major launch in the 
area of neuroscience/immuno-inflammation by 2030. Servier sets a goal of 
achieving an oncology revenue greater than or equal to Euro3 billion in 2030.

2 – Accelerate the Group's leadership in cardiometabolism and venous disease 

Servier is very involved in the development of incremental innovations (Single 
Pill Combinations) as well as innovative digital services that aim to improve 
diagnosis, knowledge of chronic diseases and therapeutic compliance. The Group 
develops partnerships with patient associations to offer services that are best 
suited to the needs of patients and their families. The Group intends to 
achieve a revenue greater than or equal to Euro3 billion in 2030 in this area 
by relying on a renowned expertise, a strong capacity for incremental 
innovation and an extensive international presence.

3 – Continue the profitable growth of the Generic business  

Relying on national champions, the Group wishes, through its Generic business, 
to facilitate access to treatments for a largest number of patients. This 
business will seize the market opportunities offered by patent exclusivity 
losses and biosimilar development, with a targeted revenue of Euro1.8 billion 
by 2030.

Three strategic levers will help achieve the Group ambition:

1 – An optimized industrial network 

To support its growth and its development, Servier will rely on an industrial 
model based on an efficient and sustainable network of specialized production 
sites, suited to the evolution of its medicines' portfolio. This model will 
also use digital technologies (Artificial Intelligence and Big data) in order 
to provide visibility into the industrial activity and to anticipate production 
management from beginning to end (end-to-end supply chain).

2 – Agile and efficient organization  

An agile and efficient organization, aligned with strategic ambitions, is a key 
performance lever. That is why Servier will strengthen cross-functional 
decision-making and collaboration in order to allow everyone within the Group 
to save time and focus on tasks with high added value. In addition, digital 
technologies will benefit all activities of the Group, and will help increase 
its effectiveness, performance and therapeutic innovation capability.

3 – A community of employees committed to future generations  

Since its creation, Servier has placed employees at the center of its actions, 
recognizing them as the Group's main strength. To make Servier 2030 a success, 
for the benefit of patients, the Group creates an environment encouraging 
talent engagement, retention and attraction.

Beyond the strong commitments already made to reduce its carbon footprint, 
accelerate diversity and inclusion and support communities, in particular 
through Mecenat Servier, the Group plans to invest in a flagship CSR project 
every three years.

A new visual identity emblematic of the Group's transformation

The transformation undertaken, of which the results are visible to all of the 
Group's stakeholders, led Servier to change its visual identity by adopting a 
brand platform that reflects the Group's renewal.

This new identity reflects what animates and represents Servier's uniqueness: 
an independent group, governed by a foundation, committed to therapeutic 
progress to serve patient needs. It is the marker of Servier's successful 
transformation, its ambitions and its renewal. It also reflects the uniqueness 
of the Group that works for the common good and fully integrates CSR into its 

The "moved by you" signature and the star symbolize the Group's proximity to 
its stakeholders (patients, partners and employees). The smile, represented by 
the curve of the "R", provides hope for patients. It symbolizes the passion, 
empathy, expertise and innovation that characterize Servier.

This new brand platform unites all employees around a common identity, a source 
of inspiration on a daily basis. It also strengthens the Group's employer 
brand: its vocation, and its independence guaranteed by its foundation status, 
respond to the younger generations' search for meaning.

Olivier Laureau, President of Servier, adds: "Our Group is founded on a 
vocation that inspires us and around strong values that drive us. The initiated 
transformation and our ambition represent a new chapter in our history. More 
than ever, with Servier 2030, we are focused on innovation and positive social 
impact thanks to an improved profitability and bold choices."

Press contact:

About Servier

Founded to serve health, Servier is a global group governed by a Foundation 
that aspires to have a meaningful social impact, both for patients and for a 
sustainable world. With its unique governance model, it can fully serve its 
vocation with a long-term vision: being committed to therapeutic progress to 
serve patient needs. The 21,800 employees of the Group are committed to this 
shared vocation, source of inspiration every day.

As a world leader in cardiology, Servier's ambition is to become a renowned, 
focused and innovative player in oncology by targeting hard-to-treat cancers. 
That is why the Group allocates over 50% of its R&D budget to developing 
targeted and innovative therapies in oncology.

Neuroscience and immuno-inflammatory diseases are the future growth driver. In 
these areas, Servier is focused on a limited number of diseases in which 
accurate patient profiling makes it possible to offer a targeted therapeutic 
response through precision medicine.

To promote access to quality care for all at a lower cost, the Group also 
offers a range of quality generic drugs covering most pathologies, relying on 
strong brands in France, Eastern Europe, Brazil and Nigeria.

In all these areas, the Group includes the patient voice at each stage of the 
life cycle of a medicine.

Headquartered in France, Servier relies on a strong geographical footprint in 
over 150 countries and achieved a revenue of Euro4.7 billion in 2021.

More information on the new Group website:

Follow us on social media: LinkedIn, Facebook, Twitter, Instagram

Logo -

[1] Inserm, 2017 

[2] Source IQVIA, Analytics Link / World 74 countries / Mat Q1 2022

SOURCE: Servier